A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

ConditionBiliary Tract Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorEisai Co., Ltd.

About this trial

The primary purpose of this study is to investigate the safety of Tasfygo.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Participants with FGFR2 fusion positive unresectable biliary tract cancer with prior chemotherapy who will receive Tasfygo tablet as per daily practice and package insert will be enrolled.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

No Intervention
Other intervention
This is a non-interventional study.

Treatment groups

60 Participants

are divided into 1 treatment group

Group A: Tasfygo tablet 35 milligrams (mg)1 intervention

Trial outcomes

Primary outcomes

Number of Participants With Adverse Drug Reactions

Time frame

Up to 1 year

Secondary outcomes

Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment

Time frame

Up to 1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eisai Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov

Apply now